A carregar...

Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar(®) in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial

BACKGROUND: Due to high cost and burden of osteoporosis, it is reasonable to focus on the reduction of fractures as the main goal of treatment. We compared the efficacy and safety of a new biosimilar recombinant human parathyroid hormone (CinnoPar®, CinnaGen, Iran) to the reference product (Forteo®,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Iran J Public Health
Main Authors: TABATABAEI-MALAZY, Ozra, NORANI, Masumeh, HESHMAT, Ramin, QORBANI, Mostafa, VOSOOGH, Afsaneh, AFRASHTEH, Behnaz, KAHKESHAN, Farzin, AJAMI, Arman, LARIJANI, Bagher
Formato: Artigo
Idioma:Inglês
Publicado em: Tehran University of Medical Sciences 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6174042/
https://ncbi.nlm.nih.gov/pubmed/30320008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!